Natural HPV immunity and vaccination strategies

Background: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. Objectives: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2000-10, Vol.19 (1), p.57-66
Main Authors: Stern, Peter L, Brown, Michael, Stacey, Simon N, Kitchener, Henry C, Hampson, Ian, Abdel-Hady, El-Said, Moore, Jim V
Format: Article
Language:English
Subjects:
AE2 gene
AE6 gene
AE7 gene
AL1 gene
AL2 gene
Biological and medical sciences
Female
Fundamental and applied biological sciences. Psychology
Human papillomavirus (HPV)
Human papillomavirus 16
Humans
Immunity, Innate
Microbiology
Oncogene Proteins, Viral - immunology
Papillomaviridae - immunology
Papillomavirus Infections - immunology
Papillomavirus Infections - prevention & control
Prophylaxis and therapy
Tumor Virus Infections - immunology
Tumor Virus Infections - prevention & control
Vaccination
Vaccines
Viral Vaccines - administration & dosage
Vulval intraepithelial neoplasia
Vulvar Neoplasms - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. Objectives: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. Conclusion: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia.
ISSN:1386-6532
1873-5967
DOI:10.1016/S1386-6532(00)00128-1